How Datwyler is Meeting the Challenge to Manufacture COVID-19 Vaccine Components.

Over the past few months, Datwyler has been working tirelessly with industry leaders to develop sealing solutions for the multiple COVID-19 vaccine candidates and find ways to manufacture the projected demand for stoppers and aluminum seals. With projects already underway, Datwyler is preparing for increased capacity demands and rapid scale-up in our facilities all over the globe.
Manufacture COVID-19 Vaccine Components

Established Vaccine Packaging Provider

The COVID-19 vaccine will join a long list of vaccines for which Datwyler has developed proven solutions. Our experienced team of experts understand the packaging requirements for vaccine products and how best to meet each drug’s specific needs. We have been working concurrently with vaccine developers to determine the best solutions for each vaccine candidate and are providing solutions in a range of sizes, compounds, and with additional treatments to ensure that each vaccine is free from contamination and meets all compatibility and functional requirements for drug delivery.

Increased Capacity

The need for increased manufacturing capacity is critical to successfully introduce a vaccine to the market. Datwyler made major investments in recent years to increase our manufacturing capacity globally, with, among others, the new Greenfield FirstLine® facility in Middletown, Delaware, USA. With this new infrastructure in place, we can support the increased demand for COVID-19 by scaling up this facility faster than originally planned. Our worldwide capacity for coated components has increased by almost 50% over the last 2 years and more investments to optimize the use of our production facilities are in the pipeline.

24/7 Production

Currently, we are ramping up production at all of our sites. This entails: utilizing all available equipment, moving to a 24/7 work schedule, implementing efficiency improvements, and investing in additional tools for each specified product. These changes will allow us to operate as effectively and efficiently as possible, so that we can continue to produce products for our existing projects while increasing production to manufacture the various COVID vaccine solutions.

Global Distribution Network

Datwyler’s 7 manufacturing sites around the world are working to design, develop, and manufacture components for the COVID vaccine. With a global distribution network already in place, we are prepared to provide our solutions to pharmaceutical companies around the globe in a timely manner. To help meet these rigorous timelines, we have put extensive measures into place at all of our facilities to manage the current, and potentially future, work restrictions that are mandated by governmental authorities. These measures not only ensure that we meet our distribution deadlines, but put the safety of our employees at the forefront, which is, and will continue to be, our priority.

Proven System Solution

Datwyler is already working with the top glass and plastic vial suppliers around the globe to develop a sealing solution for the various COVID-19 vaccines already in development. Both Datwyler’s coated and uncoated products are proven to work in all standard vials on the market. We will continue to work concurrently with pharmaceutical companies, packaging suppliers, and other healthcare industry experts to develop multiple proven system solutions.

For a vaccine that may save hundreds of thousands of lives, the stakes have never been higher. Datwyler is prepared to meet these challenges head-on and are ready to continue our fight against COVID-19.

Focus